Week of April 6, 2026

This week's 13F and Form 4 activity reflects meaningful conviction among specialist biotech allocators, with RA Capital Management emerging as the most aggressive buyer in the period ending April 6, 2026. The Boston-based life sciences fund executed three separate transactions accumulating approximately $52.4 million in Wave Life Sciences (WVE), signaling strong conviction in the RNA-targeting platform ahead of anticipated clinical milestones. RA Capital also disclosed a $7.4 million purchase in Mineralys Therapeutics (MLYS), a hypertension-focused company developing targeted aldosterone synthase inhibitors, suggesting the fund is building exposure across multiple stages of the clinical pipeline. Elsewhere, OEP VII GP acquired roughly $24.3 million in AdaptHealth (AHCO) across four transactions, while Pale Fire Capital SE added $8.2 million to its position in Phreesia (PHR) and Fairmount Funds Management initiated a $3.0 million purchase in Zentalis Pharmaceuticals (ZBIO), the latter noteworthy given Fairmount's track record as a disciplined oncology-focused allocator.

On the catalyst front, investors should be tracking several near-term binary events that could generate meaningful price action across large- and mid-cap names. Pfizer (PFE) is facing back-to-back readouts, with Phase 2 data on maplirpacept (PF-07901801) due today and results from its MET233 program expected April 15, giving the large-cap a concentrated two-week catalyst window that institutional desks will be watching closely. Exelixis (EXEL) is scheduled to report Phase 2 data on cabozantinib on April 12, a readout with potential label-expansion implications in a competitive solid tumor landscape. Incyte (INCY) follows on April 14 with Phase 2 results for retifanlimab, its PD-1 inhibitor competing in an increasingly crowded immuno-oncology market, while Regeneron (REGN) rounds out the month with Phase 2 fianlimab data due April 17, a program that has drawn considerable buy-side attention given the asset's differentiated LAG-3 mechanism.

The convergence data this week points to a clear cluster of specialist interest around targeted protein degradation and rare disease platforms. Kymera Therapeutics (KYMR) stands out as the highest-conviction shared holding, with nine funds maintaining aggregate exposure of approximately $2.1 billion — a level of concentration that reflects broad institutional alignment on the company's STAT6 and IRAK4 degrader programs. Edgewise